AN2 Therapeutics (ANTX) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Organigram Global (OGI) over the past year, gaining 184.0% versus a loss of 49.1%. Organigram Global is the larger company by market cap ($133.6 million vs $127.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | OGI |
|---|---|---|
| Share price | $3.38 | $0.9267 |
| Market cap | $127.55M | $133.59M |
| 1-day change | -6.11% | -0.53% |
| YTD return | +196.49% | -44.84% |
| 1-year return | +184.03% | -49.08% |
| 5-year return | — | -90.10% |
| P/E ratio (TTM) | — | 2.16 |
| Forward P/E | — | 38.61 |
| EPS (TTM) | $-1.05 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-35.17M | — |
| 52-week high | $7.19 | $2.24 |
| 52-week low | $1.00 | $0.853 |
| Distance from 52-week high | -52.99% | -58.63% |
| Analyst consensus | none | buy |
| Avg. price target upside | +166.27% | — |
| Average volume | 251.53K | 855.47K |
| Shares outstanding | 37.74M | 144.15M |
| Employees | 21 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed OGI by 233.1 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
ANTX vs OGI FAQ
Which is bigger, AN2 Therapeutics or Organigram Global?
Organigram Global (OGI) is larger, with a market capitalization of $133.59M compared with $127.55M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ANTX or OGI?
ANTX returned +184.03% over the past 12 months, compared with -49.08% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Organigram Global in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.